We are live on
!
Find out more
Cardiff Oncology
CRDF
CRDF
62 hedge funds and large institutions have $6.47M invested in Cardiff Oncology in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.01% less ownership
Funds ownership: 0.26% → 0.25% (-0.01%)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
9% less funds holding
Funds holding: 68 → 62 (-6)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
46% less capital invested
Capital invested by funds: $12.1M → $6.47M (-$5.61M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $76K
Holders
62
Holders Change
-6
Holders Change %
-8.82%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
19
Reduced
20
Closed
8
Calls
–
Puts
$76K
Net Calls
-$76K
Net Calls Change
+$106K
Top Buyers
| 1 |
BlackRock
New York
|
+$3.14M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$337K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$165K |
| 4 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$120K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$80.8K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$317K |
| 2 |
Morgan Stanley
New York
|
-$169K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$156K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$141K |
| 5 |
Citigroup
New York
|
-$53.2K |
